A cell-permeable uricosuric agent that, in addition to itsknown efficacy in gout treatment, acts as a reversible CaCC blocker and isreported to be more potent than NFA and NPPB in suppressing500 nM Ionomycin induced I- influx in TMEM16A-expressing HEK293cells (IC50 = 9.97, 140, and 150 µM, respectively) as well as inblocking voltage-gated Cl- current in TMEM16B-expressing HEK293cells, while exhibiting much reduced potency against ENaC (α, β, and γ) orCFTR. Shown to significantly reduce mucin secretion from NHBE (normal humanbronchial epithelial) and suppress human ASM (airway smooth muscle) contractionupon muscarinic receptor stimulation.

Primary Target
TMEM16A-CaCC

Reversible: yes

Packaged under inert gas

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.

Kobayashi, K., et al. 2012. Drug Metab. Pharmacokinet. In press.
Zhang, C.H., et al. 2013. Am. J. Respir. Crit. Care Med.187, 374.
Huang, F., et al. 2012. Proc. Natl. Acad. Sci. USA.109, 16354.
Fujimori, S., et al. 2011. Nucleosides Nucleotides Nucleic Acids30, 1035.
Perez-Ruiz, F., et al. 1998. Ann. Rheum. Dis.57, 545.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Toxic (F)